Research programme: amyotrophic lateral sclerosis vaccines - Amorfix

Drug Profile

Research programme: amyotrophic lateral sclerosis vaccines - Amorfix

Latest Information Update: 18 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences
  • Class Vaccines
  • Mechanism of Action Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Amyotrophic lateral sclerosis

Most Recent Events

  • 08 Aug 2014 Suspended - Preclinical for Amyotrophic lateral sclerosis in Canada (Parenteral)
  • 13 Aug 2013 Research programme: amyotrophic lateral sclerosis vaccines - Amorfix is available for licensing as of 13 August 2013. http://www.amorfix.com
  • 30 Jun 2013 Amyotrophic lateral sclerosis vaccines no longer licensed to Pan-Provincial Vaccine Enterprise
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top